JP Morgan Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $510
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Jessica Fye maintains an Overweight rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and raises the price target from $505 to $510.
August 05, 2024 | 2:56 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JP Morgan analyst Jessica Fye maintains an Overweight rating on Vertex Pharmaceuticals and raises the price target from $505 to $510.
The Overweight rating and increased price target from a reputable analyst at JP Morgan is likely to positively influence investor sentiment and drive short-term price appreciation for Vertex Pharmaceuticals.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100